Zumandimine Kit
Product Images NDC 59651-030

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Zumandimine (NDC 59651-030). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aurobindo Pharma Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1: Vte Risk With Drospirenone And Ethinyl Estradiol Relative To Lng-containing Cocs (adjusted Risk#) (Drospirenone Fig1)

A forest plot chart showing hazard ratios and odds ratios from multiple studies, including prospective cohort, retrospective cohort, case-control, and non-fatal idiopathic cases only. Study names like Ingenix, EURAS, LASS, FDA-funded, Danish, MEGA, German case-control, PharMetrics, and GPRD are listed with their corresponding data points and confidence intervals on a logarithmic scale from 0.1 to 10.*

FDA Label Image

Figure 2 Likelihood Of Developing A Vte (Drospirenone Fig2)

A horizontal bar chart depicting the number of women with a blood clot per 10,000 women years (WY) across four groups: Non-Pregnant Non-COC users, COC users, Pregnant women, and Postpartum women (12 weeks only). The chart shows increasing ranges from 1-5 in Non-Pregnant Non-COC users to 40-65 in Postpartum women. Additional notes explain pregnancy data assumptions and risk ranges.*

FDA Label Image

Figure3 (Drospirenone Fig3)

A forest plot comparing effect estimates of contraceptive use on various studies. It displays odds ratios (OR) and relative risks (RR) with confidence intervals for ever combined oral contraceptive (COC) use versus never use, and current COC use versus never use, across multiple cohort studies published between 2002 and 2017.*

FDA Label Image

Drospirenone-fig4 (Drospirenone Fig4)

A vertical infographic illustrating pregnancy rates per 100 women in one year relative to contraception methods. The chart ranks methods from fewer pregnancies at the top (implants, injections, intrauterine devices, sterilization) to more pregnancies at the bottom (no birth control). Birth control pills, skin patch, and vaginal ring with hormones are positioned near the top; condoms and diaphragms in the middle; and methods like no sex during fertile days, spermicide, and withdrawal below them.*

FDA Label Image

Figure5 (Drospirenone Fig5)

Label for Zumandimine kit containing drospirenone and ethinyl estradiol tablets, USP 3 mg/0.03 mg. Displays a 4-week circular day pill organizer with circles marked Sunday through Saturday. Includes storage guidance at 20° to 25°C and labeler information for Aurobindo Pharma USA, Inc., East Windsor, NJ. Also notes manufacturing in India with code TS/DRUGS/22/2009 and the NDC 59651-030-28.*

FDA Label Image

Drospirenone-fig6 (Drospirenone Fig6)

A bar chart comparing the number of women with a blood clot per 10,000 women years among different groups: Non-Pregnant Non-COC users, COC users, pregnant women, and postpartum women (12 weeks only). The chart shows numerical ranges for each group, illustrating increased blood clot risk from Non-COC users to postpartum women.*

FDA Label Image

Drospirenone-fig7 (Drospirenone Fig7)

Zumandimine kit label for drospirenone and ethinyl estradiol tablets, USP 3 mg/0.03 mg by Aurobindo Pharma Limited. The label indicates it contains one blister pack of 28 tablets intended for oral contraception. It includes storage instructions and space for pharmacy labeling, with the NDC 59651-030-28 shown.*

FDA Label Image

Drospirenone Fig8

Packaging label for Zumandimine 3 mg/0.03 mg tablets, a kit containing drospirenone and ethinyl estradiol. The label shows this is a human prescription drug by Aurobindo Pharma Limited. It includes directions on blister pack contents and storage instructions. The package holds one blister pack of 28 tablets, distributed by Aurobindo Pharma USA Inc.*

FDA Label Image

Structure (Drospirenone Str)

Chemical structure diagram showing the molecular structures of Drospirenone and Ethinyl Estradiol, the active ingredients in Zumandimine. The structure on the left represents Drospirenone, and the structure on the right represents Ethinyl Estradiol.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.